News

May 23, 2012 — Accumetrics Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents,...

The U.S. Food and Drug Administration (FDA) today approved generic versions of the blood-thinning drug Plavix (clopidogrel), which is expected to have a major impact on the cost to treat patients...

May 15, 2012 — Reaching out to patients with a few simple phone calls significantly improves the likelihood they’ll continue to take critically important medication that...

April 6, 2012 — The U.S. anticoagulant market is on the verge of a major shift in clinical practice, transitioning from a market dominated by a single injectable anticoagulant to a highly...

March 29, 2012 — Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in a specific group of...

March 27, 2012 – Researchers found the antiplatelet drug abciximab significantly decreased damage to the heart muscle in patients with ST-segment-elevation myocardial infarction (STEMI), the most...

March 8, 2012 — Transgenomic Inc. announced the publication of a new study by researchers at Vanderbilt University that further validates the role of both genes found in the company’s PGxPredict:...

February 28, 2012 — Janssen Research and Development LLC announced that the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental new drug...

February 23, 2012 — AstraZeneca announced that the American College of Chest Physicians (ACCP) has updated its guidelines on Antithrombotic Therapy and Prevention of Thrombosis to include a...

 

January 19, 2012 – New findings from a research study led by physicians at Scripps Health reveal that the investigational drug cangrelor can achieve very fast blood thinning effects...

January 9, 2012 – Janssen Research and Development, LLC (JRD) announced today that it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA)...

January 5, 2011 – Bayer HealthCare's oral anticoagulant tablet Xarelto (rivaroxaban) has been approved for use in the United Kingdom in two important blood-clotting disorders

November 18, 2011 – An analysis of the TRITON-TIMI 38 trial presented today in an oral session at the American Heart Association (AHA) Scientific Sessions meeting examined the effect of Effient (...

November 16, 2011 — Non-adherence to antiplatelet therapy – which prevents blood clots following percutaneous coronary intervention (PCI) – was associated with higher rates of both ischemic and...

November 16, 2011 – Johnson & Johnson Pharmaceutical Research & Development announced that adding oral rivaroxaban to standard antiplatelet therapy significantly reduced the composite...

November 15, 2011 — A clinical trial of patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) and stable angina showed rapid genotyping followed by...

November 15, 2011 — A clinical trial comparing prasugrel to clopidogrel for patients with high on-clopidogrel platelet reactivity (HCPR) following percutaneous coronary intervention (PCI) was...

November 15, 2011 — Results of ADAPT-DES (Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents) were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT)...

November 15, 2011 — Data from the BRIDGE clinical trial demonstrate that intravenous use of the drug cangrelor was effective at maintaining platelet inhibition in patients on thienopyridines who...

November 11, 2011 — The 30-day results from the 8,500+ patient ADAPT-DES registry were presented at the 2011 TCT conference in San Francisco. Patients with high platelet reactivity, as measured by...